<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00267553</url>
  </required_header>
  <id_info>
    <org_study_id>Biomed 777-CLP-32</org_study_id>
    <nct_id>NCT00267553</nct_id>
  </id_info>
  <brief_title>Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer</brief_title>
  <official_title>Open Label Treatment and Survival Continuation Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intarcia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intarcia Therapeutics</source>
  <brief_summary>
    <textblock>
      Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29,
      and will continue to compare combined hormonal therapy using the experimental aromatase
      inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene
      (Fareston®), to the single agent FDA-approved aromatase inhibitor letrozole (Femara®) for the
      treatment of advanced breast cancer. The purpose of this study is to determine whether
      maximal estrogen suppression achieved via the combination of atamestane, plus toremifene
      (Fareston®), is more effective than letrozole (Femara®) in delaying the growth of breast
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aromatase is an enzyme expressed in tissues such as muscle and fat in postmenopausal women.
      These non-ovarian tissues become the dominant sources of estrogen in postmenopausal women.
      Breast cancer cells are often very dependent on estrogens to continue to grow. Atamestane
      blocks the formation of estrogens from androgenic precursors in the body via the aromatase
      enzyme. Toremifene blocks circulating and intracellular estrogens from stimulating estrogen
      receptors in breast cancer cells. The goal of therapy with atamestane, an aromatase
      inhibitor, in combination with the estrogen receptor antagonist, toremifene, is to achieve
      complete suppression of estrogen stimulation of breast cancer cells. This study is designed
      to determine whether combined hormonal therapy will lengthen the time to disease progression
      and the survival time for subjects with advanced breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint
  </why_stopped>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In conjunction with the data from Biomed 777-CLP-29, compare the time to progression (TTP) in the atamestane plus toremifene arm to the TTP in the letrozole plus placebo arm</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>In conjunction with the data from Biomed 777-CLP-29, obtain safety, survival and time to treatment failure (TTF) data for both arms in this continuation study.</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Neoplasms, Hormone-Dependent</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atamestane</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>toremifene</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be eligible to receive continued treatment, subjects must remain eligible to
             receive study drug at the time of their last Biomed 777-CLP-29 visit

          -  To continue on survival follow-up, subjects must be in survival follow-up in study
             Biomed 777-CLP-29

          -  Written informed consent obtained for subjects who continue study drug treatment

        Exclusion Criteria:

          -  Subjects who have withdrawn consent to participate in Biomed 777-CLP-29 for any reason

          -  Subjects for whom the investigator considers study participation is no longer in the
             best interest of those subjects.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Langecker, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Intarcia Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Joseph</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lacey</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leningrad Region</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lipetsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murmansk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>N. Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Obninsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stavropol</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivano-Frankovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krivoy Rog</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2005</study_first_submitted>
  <study_first_submitted_qc>December 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2005</study_first_posted>
  <last_update_submitted>September 7, 2007</last_update_submitted>
  <last_update_submitted_qc>September 7, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2007</last_update_posted>
  <keyword>Atamestane</keyword>
  <keyword>Breast neoplasms</keyword>
  <keyword>Combined hormonal therapy</keyword>
  <keyword>Complete estrogen blockade</keyword>
  <keyword>Ductal breast carcinoma</keyword>
  <keyword>Estrogen blocker</keyword>
  <keyword>Fareston®</keyword>
  <keyword>Femara®</keyword>
  <keyword>First line therapy</keyword>
  <keyword>Letrozole</keyword>
  <keyword>Lobular breast carcinoma</keyword>
  <keyword>Locally advanced breast cancer</keyword>
  <keyword>Locally recurrent breast cancer</keyword>
  <keyword>Maximal estrogen inhibition</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Neoplasms, Hormone-dependent</keyword>
  <keyword>Receptor-positive</keyword>
  <keyword>Stage IIIA breast cancer</keyword>
  <keyword>Stage IIIB breast cancer</keyword>
  <keyword>Stage IV breast cancer</keyword>
  <keyword>Toremifene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Hormone-Dependent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Toremifene</mesh_term>
    <mesh_term>Atamestane</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

